Cytori Therapeutics Inc (NASDAQ:CYTX) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $7.42.

Several research firms have issued reports on CYTX. ValuEngine upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 4th. Maxim Group downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. HC Wainwright decreased their price objective on shares of Cytori Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, August 15th. Finally, Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Tuesday, July 31st.

NASDAQ:CYTX traded down $0.05 during trading hours on Friday, hitting $0.53. The company’s stock had a trading volume of 490,669 shares, compared to its average volume of 1,196,959. The firm has a market capitalization of $4.08 million, a PE ratio of -0.08 and a beta of 2.55. Cytori Therapeutics has a 52-week low of $0.31 and a 52-week high of $8.70.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.09). Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $2.50 million. equities research analysts anticipate that Cytori Therapeutics will post -0.85 EPS for the current fiscal year.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Read More: What is the NASDAQ?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.